Neogenomics, inc. (NEO)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues [Abstract]
Total revenue

419,283

408,830

378,438

342,862

308,895

276,741

261,687

251,728

246,246

240,251

227,043

228,667

229,532

231,808

210,874

175,239

136,480

99,802

97,522

95,613

91,913

87,069

80,392

74,059

68,992

66,467

63,038

60,356

60,364

59,867

57,866

54,984

49,839

43,484

39,299

36,469

0

0

0

COST OF REVENUE

223,193

211,994

194,414

177,349

161,818

149,476

144,772

142,239

139,935

138,295

136,867

136,041

135,653

133,704

115,523

96,062

75,095

56,046

54,522

53,490

50,364

46,355

41,987

37,777

35,792

34,730

34,031

33,628

33,426

33,031

31,630

29,566

27,132

24,056

21,814

20,143

0

0

0

Pharma Services & research revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

BioPharma & research revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

GROSS PROFIT

196,090

196,836

184,024

165,513

147,077

127,265

116,915

109,489

106,311

101,956

90,176

92,626

93,879

98,104

95,351

79,177

61,385

43,756

43,000

42,123

41,549

40,714

38,405

36,282

33,200

31,737

29,007

26,728

26,938

26,836

26,236

25,418

22,707

19,428

17,485

16,326

0

0

0

Operating expenses:
General and administrative

132,195

127,993

120,490

108,491

99,897

84,822

75,746

72,959

70,408

70,359

61,835

62,592

62,939

63,926

68,405

56,818

45,114

33,631

27,549

26,481

25,276

23,808

22,117

20,082

18,276

17,397

16,672

16,266

16,268

15,843

15,276

14,529

13,377

12,331

11,719

11,306

0

0

0

Research and development

9,338

8,487

6,933

4,768

3,254

3,001

3,032

3,856

3,730

3,636

4,009

3,706

4,065

4,649

5,574

5,478

4,975

4,198

2,757

2,900

2,730

2,689

2,924

2,250

2,233

2,440

2,239

2,707

2,619

2,281

1,960

1,277

921

543

0

0

0

-

-

Sales and marketing

49,392

47,350

43,095

38,487

33,843

29,402

27,213

26,676

25,128

24,001

23,968

23,563

23,758

23,910

21,078

17,868

14,448

11,562

11,794

12,029

12,280

11,999

11,261

10,614

9,428

8,726

7,931

7,434

7,396

7,501

7,610

7,496

7,246

6,963

7,145

7,363

0

0

0

Loss on sale of business

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

190,925

183,830

170,518

151,746

136,994

117,225

105,991

104,549

100,324

99,054

94,334

93,325

94,226

95,949

95,057

80,164

64,537

49,391

42,100

41,410

40,286

38,496

36,302

32,946

29,937

28,563

26,842

26,407

26,283

25,625

24,846

23,302

21,544

19,837

19,280

18,960

0

0

0

(LOSS) INCOME FROM OPERATIONS

5,165

13,006

13,506

13,767

10,083

10,040

10,924

4,940

5,987

2,902

-4,158

-699

-347

2,155

294

-987

-3,152

-5,635

900

713

1,263

2,218

2,103

3,336

3,263

3,174

2,165

321

655

1,211

1,390

2,116

1,163

-409

-1,795

-2,634

0

0

0

Interest expense and debt termination fees, net

2,706

3,713

4,797

6,467

6,570

6,230

14,479

11,208

8,390

5,540

10,334

10,264

10,227

9,998

-3,422

-2,193

-934

854

0

0

0

-

-

-

-

-

-

-

0

-

1,059

953

844

768

0

0

0

-

-

Other (income) expense

762

-4,630

-5,079

-5,084

-5,218

14

-43

-73

51

-12

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of debt

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

INTEREST AND OTHER EXPENSE  NET

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

0

0

Loss before taxes

2,203

3,645

2,612

1,198

-1,705

3,824

4,748

-791

376

-2,650

-13,820

-10,431

-10,116

-7,843

-2,446

-2,498

-3,404

-4,489

84

-82

404

1,289

1,126

2,346

2,294

2,185

1,108

-796

-518

65

331

1,163

319

-1,177

0

0

0

-

-

Income tax expense (benefit)

-1,249

-4,361

549

-745

-1,277

1,184

-2,089

-1,341

-1,037

-2,254

-2,231

-3,039

-2,654

-1,701

-1,474

-1,468

-1,785

-1,954

99

99

135

157

184

213

162

152

0

0

0

-

-

-

-

0

0

0

0

-

-

NET LOSS

3,452

8,006

2,063

1,943

-428

2,640

6,837

550

1,413

-396

-11,589

-7,392

-7,462

-6,142

-972

-1,030

-1,619

-2,535

-15

-181

269

1,132

942

2,133

2,132

2,033

1,062

-813

-535

65

331

1,163

319

-1,177

-2,527

-3,362

0

0

0

Deemed dividends on preferred stock and amortization of beneficial conversion feature

-

-

1,853

1,853

-

5,627

11,586

12,498

10,656

10,547

15,226

16,154

17,065

18,011

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of preferred stock beneficial conversion feature

-

-

-

-

-

-

-

-

7,083

-

603

2,591

4,608

6,663

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on redemption of preferred stock

-

-

0

0

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS

-

-

2,063

1,943

-

6,088

7,594

-1,344

-9,424

-10,943

-27,418

-26,137

-29,135

-30,816

-17,795

-12,286

-7,308

-2,657

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NET LOSS PER SHARE
Basic (in dollars per share)

-0.07

0.07

0.02

0.02

-0.03

0.01

0.02

0.07

-0.03

0.03

-0.09

-0.03

-0.05

-0.19

-0.07

-0.07

-0.07

-

-

-

-

-

-

-

-

-

0.02

0.01

-

-

-

-

-

-

-

-

-

-

-

Diluted (in dollars per share)

-0.07

0.07

0.02

0.02

-0.03

0.01

0.02

0.07

-0.03

0.03

-0.09

-0.03

-0.05

-0.19

-0.07

-0.07

-0.07

-

-

-

-

-

-

-

-

-

0.02

0.01

-

-

-

-

-

-

-

-

-

-

-

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.00

0.00

-0.01

-

-0.01

0.01

0.00

-

-

-

0.00

0.00

-0.02

0.01

0.01

0.00

0.00

-0.01

-0.02

-

-

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.00

0.00

-0.01

-

-0.01

0.01

0.00

-

-

-

0.00

0.00

-0.02

0.01

0.01

0.00

0.00

-0.01

-0.02

-

-

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic (in shares)

104,484

104,944

103,899

98,297

94,740

93,695

87,253

81,017

80,507

80,024

79,617

79,413

78,650

78,507

78,145

77,448

76,068

60,865

60,537

60,425

60,277

60,321

54,444

49,890

49,277

49,062

48,933

48,793

46,264

134,843

45,175

44

44

43,337

43,104

42,857

41,734

-

-

Diluted (in shares)

104,484

109,504

107,880

102,336

94,740

104,698

90,899

90,168

80,507

80,024

79,617

79,413

78,650

78,507

78,145

77,448

76,068

60,865

60,537

60,425

60,277

62,418

54,444

53,733

53,469

53,260

53,173

53,744

50,923

149,589

45,175

47

47

43,337

43,104

42,857

41,734

-

-

NET LOSS PER SHARE - Basic and Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.03

-0.03

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - Basic and Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

37,376

37,307

Clinical Services
Total revenue

367,933

361,161

333,670

300,554

271,112

241,873

229,416

221,154

217,161

213,097

203,123

207,675

208,444

210,159

193,503

162,639

130,378

98,595

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

COST OF REVENUE

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

GROSS PROFIT

0

-

0

0

0

-

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Pharma Services
Total revenue

51,350

47,669

44,768

42,308

37,783

34,868

32,271

30,574

29,085

27,154

23,920

20,992

21,088

21,649

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

COST OF REVENUE

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

GROSS PROFIT

0

-

0

0

0

-

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-